{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kroidl I"],"funding":["University Hospital, LMU Munich","Universitätsklinik München","Euroimmun and Roche provided kits and machines for analyses at discounted rates for the study","Bavarian State Ministry of Science and the Arts","European-wide Consortium ORCHESTRA","German Ministry for Education and Research"],"pagination":["200"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10474769"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["<h4>Background</h4>Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU).<h4>Methods</h4>To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 "],"journal":["Virology journal"],"pubmed_title":["Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison."],"pmcid":["PMC10474769"],"funding_grant_id":["01KI20271","101016167"],"pubmed_authors":["Weigl N","Keßler A","Leidl R","Gasser M","Schandelmaier P","Puchinger K","Thiel V","Mayrhofer R","Durner J","Golschan E","Bohnlein R","Kroidl I","Struber L","Noller JMG","Haselwarter T","Wustrow P","Huber K","Pritsch M","Kroidl A","Struber A","Gutierrez P","Caroli F","Bitzer P","Guglielmini EM","Sedlmeier J","Alamoudi E","Herrmann M","Bednarski F","Baldassarre V","Fischer S","Markgraf A","Zielke A","Fingerle V","Wolfl R","Janke C","Plank M","Schafer N","Lapteva E","Gari M","Coleman J","Do A","Eser T","Gauder S","Beyerl J","Frese J","Rubio-Acero R","Zimmermann T","Deak F","Horn S","Zeggini E","Laxy M","Eberle U","Geisenberger O","Radon K","Diepers P","Castelletti N","Dobler G","Norena I","Schluse B","Thiesbrummel S","Hillmann S","Baumann M","Pleimelding C","Hillari L","Halfmann C","Tang J","Wallrauch C","Britz V","Le Gleut R","Strobl K","Nikolaides S","Schneider A","Raimundez E","Grauvogl V","Liedl L","Thur N","Eckstein J","Kresin J","Lucaj X","Hinske C","Diekmannshemke J","Geier R","Luppa F","Metaxa D","Von Lovenberg E","Bakuli A","Fensterseifer H","Theis F","Nafziger AS","Zuche L","Kiani C","Raschka J","Maczka A","Schneider L","Gezgin K","Heiber A","Kreider N","Ruci V","Contento L","Thumser E","Hofinger M","Hofmann L","Schalte Y","Gilberg L","Diefenbach MN","Wieser A","Lucke E","Niermeyer K","Ahmed MIM","Von Lovenberg J","Muller K","Pruckner S","Lang M","Schunk M","Mekota AM","Poll V","Brauer A","Pletschette M","Hoelscher M","Lang C","Pattard L","Reinkemeyer C","Ullrich J","Matcau P","Feyereisen M","Bruger J","Froschl G","Waibel J","Lange S","Wolff J","Zimmer T","Czwienzek A","Gillig K","Hernandez A","Bunz F","Hofberger T","Nascimento N","Hartinger L","Haderer A","Klugherz I","Rothe C","Vos C","Zange S","Eser TM","Lindner F","Mang P","Kappl U","Falk P","Muller H","Brand I","Behlen M","Becker M","Mohr E","Pusl K","Riess F","Paunovic I","Khan Z","Girl P","Hoefflin J","Kunder P","Reich J","Soler A","Schultz S","Geldmacher C","Thomschke A","Guggenbuhl J","Wurfel T","Karger L","Hasenauer J","Heller L","Sothmann P","Winter S","Wullinger P","Schwettmann L","Sintu-Sempta L","Saathoff E","KoCo19/ORCHESTRA Study Group","Anderson J","Putz P","Olbrich L","Forster F","Hannes M","Bemirayev O","Vollmayr V","Fuchs C"],"additional_accession":[]},"is_claimable":false,"name":"Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison.","description":"<h4>Background</h4>Measuring specific anti-SARS-CoV-2 antibodies has become one of the main epidemiological tools to survey the ongoing SARS-CoV-2 pandemic, but also vaccination response. The WHO made available a set of well-characterized samples derived from recovered individuals to allow normalization between different quantitative anti-Spike assays to defined Binding Antibody Units (BAU).<h4>Methods</h4>To assess sero-responses longitudinally, a cohort of ninety-nine SARS-CoV-2 RT-PCR positive subjects was followed up together with forty-five vaccinees without previous infection but with two vaccinations. Sero-responses were evaluated using a total of six different assays: four measuring anti-Spike proteins (converted to BAU), one measuring anti-Nucleocapsid proteins and one SARS-CoV-2 ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2025-04-18T18:48:44.405Z","creation":"2024-11-08T22:53:52.194Z"},"accession":"S-EPMC10474769","cross_references":{"pubmed":["37658454"],"doi":["10.1186/s12985-023-02167-z"]}}